Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.

Front Oncol · 2026 · PMC12992051 · PMID 41853305

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Additionally, the presence of extramedullary disease demonstrated a trend toward shorter overall survival, although this did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Discussion In our study, in the daratumumab-treated cohort, patients with 1q gain or amplification showed a trend towards a shorter PFS and patients with 1q amplification presented with a shorter OS, consistent with the concept that amplification reflects a more advanced cytogenetic event.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.